Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-02-13
2009-12-08
Bragdon, Kathleen Kerr (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S841000, C424S278100, C424S548000
Reexamination Certificate
active
07629308
ABSTRACT:
The present invention relates to the polypeptides known as muscle calcineurin interacting proteins (MCIPs). These molecules binding to calcineurin and, in so doing, modulate its functions, which includes phosphate removal as part of a pathway coupling Ca2+to cellular responses in muscle. MCIPs form a physical complex with the catalytic subunit of calcineurin, and increased levels of MCIPs correspond to a reduced ability of calcineurin to stimulate transcription of certain target genes. Methods to exploit these observation are provided and include screening for modulators of MCIP expression and binding to calcineurin, methods of diagnosis of MCIP defects, and methods for treating cardiomyopathies, including cardiac hypertrophy.
REFERENCES:
patent: 4330557 (1982-05-01), Cavazza
patent: 5651980 (1997-07-01), Lanza et al.
patent: 5869318 (1999-02-01), Palleja et al.
patent: 5958404 (1999-09-01), Selawry
patent: 6673604 (2004-01-01), Edge
patent: WO 99 19473 (1999-04-01), None
patent: WO 99 50410 (1999-10-01), None
patent: WO 00 09667 (2000-02-01), None
patent: WO 02/04491 (2002-01-01), None
Rothermel, B. et al. (2000) A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J. Biol. Chem. vol. 275, pp. 8719-8725.
Fuentes, J. J. et al. (2000) DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Human Mol. Genet. vol. 9, pp. 1681-1690.
Miyazaki, T. et al. (1996) Molecular cloning of a novel thyroid hormone-responsive gene, ZAKI-4, in human skin fibroblasts. J. Biol. Chem. vol. 271, pp. 14567-1471.
Chin E. R. et al. (1998) A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. vol. 12, pp. 2499-2509.
Sussman, M. A. et al. (1998) Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. vol. 281, pp. 1690-1693.
Yang J. et al. (2000) Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res. vol. 87, pp. e61-e68.
Berchtold, M. W. et al. (2000) Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol Rev. vol. 80, pp. 1215-1265. Review.
Dunn, S. E. et al. (2002) Calcineurin and skeletal muscle growth. Nat. Cell Biol. vol. 4, p. E46-47.
Colao, A. et al. (1999) Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab. vol. 84, pp. 17-23.
Vega, R. B. et al. (2003) Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci U S A. vol. 100, pp. 669-674.
Ohkawa et al. (2003) Calcineurin-mediated pathway involved in the differentiated phenotype of smooth muscle cells.Biochem. Biophys. Res. Commun. vol. 301, No. 1, pp. 78-83.
Kessen et al. (1999) Ca(2+)/calmodulin-independent activation of calcineurin from Dictyostelium by unsaturated long chain fatty acids. J. Biol. Chem. vol. 274, No. 53, pp. 37821-37826.
Hilioti et al. (2003) GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs, Genes Dev., vol. 18, No. 1, pp. 35-47.
Beals et al., “Nuclear localization of NF-Atc by a calcineurin-dependent, cyclosporin-sensetive intramolecular interaction,”Genes Dev., 11:824-834, 1997.
Chin et al., “A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type,”Genes Dev., 12:2499-2509, 1998.
Crabtree, “Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT,”Cell, 96:611-614, 1999.
Ding et al., “Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin,”Circ Res., 84:729-734, 1999.
Dunn et al., “Calcineurin is required for skeletal muscle hypertrophy,”J Biol Chem., 274:21908-21912, 1999.
Eto et al., “Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training,”Circulation, 101:2134-2137, 2000.
Friddle et al., “Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy,”Proc. Natl. Acad. Sci. USA, 97:6745-6750, 2000.
Fuentes et al., “Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene,”Genomics, 44:358-361, 1997.
Fuentes et al., “A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart,” Abstract,Hum. Mol. Genet., 4:1935-1944, 1995.
Graef et al., “L-type calcium channels and GSK-3 regulate the activity of NF-Atc4 in hippocampal neurons,”Nature, 401:703-8, 1999.
Grayson et al., “Synergistic interactions between heterologous upstream activation elements and specific TATA sequences in a muscle-specific promoter,”Mol-Cell Biol., 15(4):1870-1878, 1995.
Grayson et al., “Collaborative interactions between MEF-2 and Sp1 in muscle-specific gene regulation,”J. Cell. Biochem., 70:366-375, 1998.
Ho et al., “NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity,”J. Biol. Chem., 270(34):19898-19907, 1995.
Ho et al., “Activation protein 1-dependent transctiptional activation of interleukin 2 gene by Ca2+/calmodulin kinase type IV/Gr,” Abstract,J. Exp. Med., 184:101-112, 1996.
Hoey et al., “Isolation of two new membes of the NF-AT gene family and functional characterization of the NF-AT proteins,” Abstract,Immunity, 2:461-472, 1995.
Kashishian et al., “AKAP79 inhibits calcineurin through a site distinct from the immunophilin-binding region,”J. Biol. Chem., 273:27412-27419, 1998.
Kingsbury and Cunningham, “A conserved family of calcineurin regulators,”Genes Dev., 14(13):1595-1604, 2000.
Klauck et al., “Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein,”Science, 271:1589-1592, 1996.
Klee et al., “Regulation of the calmodulin-stimulated protein phosphatase, calcineurin,”J. Biol. Chem., 273(22):13367-13370, 1998.
Lai et al., “Cain, a novel physiologic protein inhibitor of calcineurin,”J. Biol. Chem., 273(29):18325-18331, 1998.
Liu et al., “Cyclosporin A-sensetive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member,”EMBO J., 16:143-153, 1997.
Loh et al., “Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity,”J. Biol. Chem., 271:10884-10891, 1996.
Mann et al., “Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus”,Cell, 33:153-159, 1983.
Mao and Wiedmann, “Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons,”J. Biol. Chem., 274:31102-31107, 1999.
Mao et al., “Neuronal activity-dependent cell survival mediated by transcription factor MEF2,”Science, 286:785-790, 1999.
Mesaeli et al., “Calreticulin is essential for cardiac development,”J. Cell Biol., 144:857-868, 1999.
Miyazaki et al., “Molecular cloning of a novel thyroid hormone-responsive gene, ZAKI-4, in human skin fibroblasts,”J Biol Chem., 271:14567-14571, 1996.
Molkentin et al., “A calcineurin-dependent transcriptional pathway for cardiac hypertrophy,”Cell, 93:215-228, 1998.
Musaro et al., “IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1,”Nature, 400:581-585, 1999.
Naya et al., “Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo,”J. Biol. Chem., 275:4545-4548, 2000.
O'Keefe et al., “FK-506- and CsA-sensetive activation of the interleukin-2 promoter by calcineurin,”Nature, 357:692-694, 1992.
Rothermel et al., “
Rothermel Beverly
Williams R. Sanders
Board of Regents , The University of Texas System
Bragdon Kathleen Kerr
Fulbright & Jaworski
Liu Samuel W
LandOfFree
Methods relating to muscle selective calcineurin interacting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods relating to muscle selective calcineurin interacting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods relating to muscle selective calcineurin interacting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4091854